Showing 3821-3830 of 4165 results for "".
- Invirsa Completes Enrollment of Phase 1/2a Dry Eye Studyhttps://modernod.com/news/invirsa-completes-enrollment-of-phase-12a-dry-eye-study/2481619/Invirsa announced that its first clinical trial, a phase 1/2a study with the primary objective to determine safety and preliminary efficacy of Invirsa's topically administered eye drop formulation of INV-102, has completed enrollment. Subjects had moderate dry eye and dosing was well tol
- Advances in Holographic OCT Receive Heidelberg Engineering Xtreme Research Award 2023https://modernod.com/news/advances-in-holographic-oct-receive-heidelberg-engineering-xtreme-research-award-2023/2481565/Drs. Hendrik Spahr and Dierck Hillmann are being honored as winners of the 2023 Heidelberg Engineering Xtreme Research Award for their research on holographic optical coherence tomography (HOLO-OCT) and their ongoing effort to transfer this technology into clinical applications, according to
- Aviceda Announces FDA Clearance of the IND Application Enabling Phase 2 Trials for GA Drug Candidatehttps://modernod.com/news/aviceda-announces-fda-clearance-of-the-ind-application-enabling-phase-2-trials-for-geographic-atrophy-drug-candidate/2481529/Aviceda Therapeutics announced that the FDA has cleared the IND for AVD-104, enabling the company to proceed with initiating phase 2 clinical trials of its lead intravitreal ocular asset for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The Pha
- Kala Pharmaceuticals Appoints Francis Mah, MD, as Chief Medical Advisorhttps://modernod.com/news/kala-pharmaceuticals-appoints-francis-mah-md-as-chief-medical-advisor/2481501/Kala Pharmaceuticals announced the appointment of Francis Mah, MD, as Chief Medical Advisor. In this new role, Dr. Mah will provide support for Kala’s clinical development and medical activities and will play a key role in interactions with eye care professionals. Dr. Mah will serve in
- New Analysis of MRI Findings Show Uplizna Reduced the Formation of Asymptomatic Optic Nerve Lesions in People with NMOSDhttps://modernod.com/news/new-analysis-of-mri-findings-show-uplizna-reduced-the-formation-of-asymptomatic-optic-nerve-lesions-in-people-with-nmosd/2481467/Horizon Therapeutics announced the presentation of new MRI imaging data from the phase 3 clinical trial showing Uplizna (inebilizumab-cdon) reduced the formation of subclinical (asymptomatic) optic nerve lesions in people with Neuromyelitis Optica Spectrum Disorder (NMOSD). These findin
- GenSight Reports Topline Efficacy and Safety Results at 3 Years Post-Treatment with Lumevoqhttps://modernod.com/news/gensight-reports-topline-efficacy-and-safety-results-at-3-years-post-treatment-with-lumevoq/2481464/GenSight Biologics reported topline efficacy and safety results at 3 years post-treatment administration in the REFLECT phase 3 clinical trial with Lumevoq (lenadogene nolparvovec). The results show sustained efficacy and favorable safety for bilateral intravitreal injection of the gene
- Study: Iyuzeh Demonstrated Similar IOP Lowering Efficacy with a Favorable Safety Profile when Compared to Xalatanhttps://modernod.com/news/study-iyuzeh-demonstrated-similar-iop-lowering-efficacy-with-a-favorable-safety-profile-when-compared-to-xalatan-in-glaucoma-patients/2481450/Thea Pharma announced the presentation of phase 3 data on Iyuzeh (latanoprost ophthalmic solution 0.005%) by Jason Bacharach, MD, at the 2023 American Glaucoma Society (AGS) Annual Meeting. The large, pivotal clinical trial demonstrated comparable efficacy of preservative-free 
- Iridex Introduces New Research and Showcases Five Events at the AGS Meetinghttps://modernod.com/news/iridex-introduces-new-research-and-showcases-five-events-at-the-ags-meeting/2481441/Iridex announced Part 2 of the evidence-based guidelines series for MicroPulse Transscleral Laser Therapy (TLT) has been published in Clinical Ophthalmology by the international consensus panel of ten glaucoma experts[1].The publication will be available at booth #5 at the 2023 meet
- Aura Biosciences Announces Positive Interim Phase 2 Data of Belzupacap Sarotalocan for Treatment of Early-Stage Choroidal Melanomahttps://modernod.com/news/aura-biosciences-announces-positive-interim-phase-2-data-of-belzupacap-sarotalocan-for-treatment-of-early-stage-choroidal-melanoma/2481414/Aura Biosciences announced the presentation of positive interim phase 2 safety and efficacy data of belzupacap sarotalocan (bel-sar) with an average of 9 months of follow up evaluating two key clinical endpoints: tumor control, and visual acuity preservation using the suprachoroidal (SC) rou
- GenSight Biologics Announces 1 Year Safety Data and Efficacy Signals from Phase 1/2 Trial of Optogenetic Treatment Candidate for RPhttps://modernod.com/news/gensight-biologics-announces-1-year-safety-data-and-efficacy-signals-from-phase-12-trial-of-optogenetic-treatment-candidate-for-rp/2481413/GenSight Biologics announced favorable safety data and encouraging efficacy signals at 1 year post-gene therapy administration for the PIONEER phase 1/2 clinical trial evaluating GS030 for the treatment of retinitis pigmentosa (RP) in 9 patients, with a follow-up up to 4 years (n=1).